BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 102 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2021. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,078,405 | -48.8% | 375,751 | -9.9% | 0.00% | 0.0% |
| Q2 2023 | $2,106,249 | +143377.5% | 417,079 | -46.3% | 0.00% | 0.0% |
| Q1 2023 | $1,468 | +55.5% | 776,594 | +48.0% | 0.00% | 0.0% |
| Q4 2022 | $944 | -99.8% | 524,557 | +51.2% | 0.00% | – |
| Q3 2022 | $586,000 | -3.8% | 346,980 | +40.2% | 0.00% | – |
| Q2 2022 | $609,000 | -58.0% | 247,540 | -9.0% | 0.00% | -100.0% |
| Q4 2021 | $1,450,000 | -30.2% | 272,035 | +10.8% | 0.00% | 0.0% |
| Q3 2021 | $2,077,000 | -48.1% | 245,517 | -25.2% | 0.00% | -50.0% |
| Q2 2021 | $4,000,000 | +17.2% | 328,158 | +133.3% | 0.00% | 0.0% |
| Q1 2021 | $3,412,000 | -38.6% | 140,630 | -18.9% | 0.00% | -50.0% |
| Q4 2020 | $5,555,000 | +378.1% | 173,330 | +350.9% | 0.00% | +300.0% |
| Q3 2020 | $1,162,000 | +96.9% | 38,444 | +174.9% | 0.00% | 0.0% |
| Q2 2020 | $590,000 | +154.3% | 13,986 | +50.5% | 0.00% | 0.0% |
| Q1 2020 | $232,000 | – | 9,296 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $8,487,000 | 0.44% |
| Hawkeye Capital Management, LLC | 243,009 | $598,000 | 0.33% |
| Boxer Capital, LLC | 2,014,858 | $4,957,000 | 0.31% |
| Newtyn Management, LLC | 520,000 | $1,279,000 | 0.24% |
| Artal Group S.A. | 1,646,517 | $4,050,000 | 0.22% |
| DAFNA Capital Management LLC | 313,600 | $771,000 | 0.21% |
| RA Capital Management | 2,589,904 | $6,371,000 | 0.17% |
| Bellevue Group AG | 4,717,113 | $11,605,000 | 0.16% |
| MPM BioImpact LLC | 239,888 | $590,000 | 0.16% |
| K2 PRINCIPAL FUND, L.P. | 507,652 | $1,249,000 | 0.14% |